Opinion: STAT+: The NIH budget should be $100 billion per year

The Food and Drug Administration's recent approval of daraxonrasib, a novel therapeutic for pancreatic cancer, marks a significant breakthrough in the field. Developed by Revolution Medicines, this drug specifically targets the KRAS oncogene, which is found in the majority of pancreatic cancer cases and is often indicative of a terminal prognosis.

Despite decades of research, KRAS has remained a formidable challenge to treat due to its complex molecular structure. However, daraxonrasib has demonstrated remarkable efficacy in a clinical trial, where it nearly doubled the survival rate in previously treated patients with KRAS mutations. This development could provide new hope for a population of patients who previously had few options, transforming a once-certain death sentence into a condition with a significantly improved prognosis.